Enterprise Value
3.62B
Cash
773.5M
Avg Qtr Burn
N/A
Short % of Float
9.03%
Insider Ownership
1.25%
Institutional Own.
-
Qtr Updated
12/31/23
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Aristada (aripiprazole lauroxil) Details Mental health, Schizophrenia | Approved Quarterly sales | |
Vivitrol (naltrexone) Details Alcohol dependence, Opioid dependence | Approved Quarterly sales | |
LYBALVI (ALKS 3831) Details Bipolar disease, Mental health, Schizophrenia | Approved Quarterly sales | |
ALKS 2680 (RDC-264177) ( Orexin 2 Receptor Agonist) Details EDS in Idiopathic Hypersomnia
, Narcolepsy | Phase 2 Initiation |